Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 14/20 | 0.72 |
| ▸ | CACNA1G | O43497 | 13/20 | 0.72 |
| ▸ | CACNA1H | O95180 | 12/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | ITK | Q08881 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439994 | 0.87 | LMNA (0.69) | CACNA1ICACNA1GCACNA1HNPC1RAB9A | |
| SCHEMBL24335810 | 0.87 | LMNA (0.61) | CACNA1ICACNA1GCACNA1HNPC1RAB9A | |
| SCHEMBL3440074 | 0.85 | NPC1 (0.67) | CACNA1ICACNA1GCACNA1HNPC1RAB9A | |
| SCHEMBL15165811 | 0.85 | CACNA1I (0.53) | CACNA1ICACNA1GCACNA1HNPC1RAB9A | |
| SCHEMBL3440003 | 0.82 | LDHB (0.57) | CACNA1ICACNA1GCACNA1HNPC1RAB9A | |
| SCHEMBL3439964 | 0.81 | CACNA1G (0.64) | CACNA1ICACNA1GCACNA1HNPC1RAB9A | |
| SCHEMBL10241140 | 0.81 | CACNA1I (0.51) | CACNA1ICACNA1GCACNA1HNPC1RAB9A | |
| SCHEMBL2113322 | 0.80 | MAPT (0.58) | CACNA1ICACNA1GCACNA1HNPC1RAB9A | |
| SCHEMBL15165793 | 0.80 | MAPT (0.49) | CACNA1ICACNA1GCACNA1HNPC1RAB9A | |
| SCHEMBL3439966 | 0.80 | CACNA1G (0.50) | CACNA1ICACNA1GCACNA1HNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4327809-A2 | TYK2 INHIBITORS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3344624-B1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI INC (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-112062754-B | Preparation method of intermediate for synthesizing Dorzagliatin | 深圳市华先医药科技有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20210047319-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-02-18 | — | — | US | disclosed |
| CN-112062754-A | Preparation method of intermediate for synthesizing Dorzagliatin | 深圳市华先医药科技有限公司 | 2020-12-11 | — | — | CN | disclosed |
| US-10781204-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10023571-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023571-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170066763-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| US-20170066763-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| WO-2017040757-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066763-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CACNA1I 4089/4885CACNA1G 4454/4885CACNA1H 4375/4885 |
| US-10023571-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK1, JAK2 | CACNA1I 3256/4885CACNA1G 4290/4885CACNA1H 4169/4885 |
| US-20210047319-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CACNA1I 4089/4885CACNA1G 4454/4885CACNA1H 4375/4885 |
| US-10781204-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK1, JAK2 | CACNA1I 3256/4885CACNA1G 4290/4885CACNA1H 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.